When to Use Dupilumab vs Mepolizumab in Asthma
For moderate-to-severe asthma, dupilumab should be your first-line biologic choice for Type 2 asthma, while mepolizumab is specifically reserved for patients with highly eosinophilic asthma or when dupilumab is unavailable. 1
Clinical Decision Algorithm
Choose Dupilumab When:
- Type 2 asthma (elevated FeNO, blood eosinophils, or IgE) 1
- Oral corticosteroid-dependent asthma 2
- Coexisting chronic rhinosinusitis with nasal polyps (CRSwNP) - dupilumab treats both conditions simultaneously 1
- Coexisting atopic dermatitis or eosinophilic esophagitis 2
- Eosinophilic COPD overlap 1
- Patient age ≥6 years 2
Choose Mepolizumab When:
- Highly eosinophilic asthma (blood eosinophils typically ≥300 cells/μL) 1
- CRSwNP with highly eosinophilic asthma as a specific combination 1
- Dupilumab contraindicated or not tolerated
- Pregnancy planning - consider omalizumab instead 1
Evidence Supporting Dupilumab Superiority
The most recent real-world comparative effectiveness data strongly favor dupilumab:
- Dupilumab reduces asthma exacerbations by 27-32% compared to mepolizumab (HR 0.68-0.72) 3, 4
- Dupilumab reduces systemic corticosteroid prescriptions by 25% more than mepolizumab 5
- Exacerbation rates: Dupilumab 1.04-1.07/year vs Mepolizumab 1.40-1.45/year 4
- Benefits are most pronounced in patients with eosinophils ≥300 cells/μL, COPD overlap, and no prior exacerbation history 3
Practical Considerations
Biomarker Thresholds:
- Dupilumab: Works across eosinophil ranges; effective even with eosinophils <150 cells/μL if Type 2 inflammation present (elevated FeNO)
- Mepolizumab: Requires documented eosinophilia (typically ≥150-300 cells/μL minimum)
Comorbidity Advantage:
Dupilumab's multi-indication approval means you can address multiple Type 2 inflammatory conditions with one agent - a critical advantage when patients have asthma plus CRSwNP, atopic dermatitis, or eosinophilic esophagitis 2. Mepolizumab only treats asthma and CRSwNP.
Common Pitfall to Avoid:
Don't default to mepolizumab simply because eosinophils are elevated. The 2025 EUFOREA guidelines explicitly position dupilumab as first-line for Type 2 asthma, with mepolizumab reserved for the specific phenotype of "highly eosinophilic asthma" 1. The real-world evidence confirms dupilumab's superior effectiveness even in highly eosinophilic patients 3.
Dosing Simplicity:
- Dupilumab: 200-300 mg every 2 weeks (age/weight-based) 2
- Mepolizumab: 100 mg every 4 weeks
- Both can be self-administered after initial training 1
When Guidelines Diverge:
While older 2020 NAEPP guidelines 6 don't specify biologic selection hierarchy, the most recent 2025 expert consensus 1 and 2024-2025 real-world comparative studies 3, 5, 4 consistently demonstrate dupilumab's superior effectiveness. The FDA labeling supports dupilumab for eosinophilic phenotype OR oral corticosteroid-dependent asthma 2, making it more broadly applicable than mepolizumab's narrower eosinophilic indication.
Bottom line: Start with dupilumab for Type 2 asthma unless the patient has isolated highly eosinophilic asthma without other Type 2 comorbidities, in which case mepolizumab remains a reasonable alternative.